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ORIGINAL INVESTIGATION
Efficacy and safety of bempedoic 
acid for prevention of cardiovascular 
events and diabetes: a systematic review 
and meta-analysis
Xing Wang1†, Yu Zhang1,2†, Huiwen Tan1, Peng Wang2, Xi Zha2, Weelic Chong3, Liangxue Zhou1* 
and Fang Fang1* 
Abstract 
Background: Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlip-
idemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. 
Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events 
and diabetes.
Methods: We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language 
restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials 
comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events 
in statin-intolerant patients with hypercholesterolemia. The primary outcomes were major adverse cardiac events, and 
percent change in LDL-C.
Results: We identified 11 trials including a total of 4391 participants. Bempedoic acid use was associated with a 
reduction in composite cardiovascular outcome (RR 0.75, 95% CI 0.56–0.99;  I2 = 0%). Bempedoic acid reduced LDL-C 
levels (MD − 22.91, 95% CI − 27.35 to − 18.47;  I2 = 99%), and similarly reduced CRP levels (MD -24.70, 95% CI − 32.10 
to − 17.30;  I2 = 53%). Bempedoic acid was associated with a reduction in rates of new-onset or worsening diabetes 
(RR 0.65, 95% CI 0.44–0.96;  I2 = 23%).
Conclusions: Bempedoic acid in patients with hypercholesterolemia was associated with a lower risk of cardiovascu-
lar events and diabetes.
Keywords: Bempedoic acid, Prevention, Cardiovascular disease, Meta-analysis
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Background
Cardiovascular diseases are among the principal causes 
of mortality, accounting for about 1 in 3 deaths in the 
United States [1]. Therefore, preventive interventions 
from the established risk factors for such diseases are a 
high priority. Statins are the standard of care for lower 
cholesterol levels and prevention of cardiovascular 
events. However, statin intolerance is reported to prev-
alent from 7 to 29%, with the predominant symptoms 
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being muscle-related side effects [2]. Inability to toler-
ate statins leads to uncontrolled cholesterol levels and 
insufficient cardiovascular risk reduction. To reduce car-
diovascular risk in these patients, the 2018 multisociety 
guidelines advocate the addition of non-statin agents [3].
Bempedoic acid (Esperion Therapeutics Inc, Ann 
Arbor, MI), as a small molecule inhibitor of ATP-citrate 
lyase, is an oral, once-daily, first-in-class drug being 
developed for the treatment of hyperlipidemia by inhib-
iting cholesterol synthesis [4]. Randomized clinical tri-
als have shown the efficacy of bempedoic acid treatment 
on lowering low-density lipoprotein–cholesterol [5–17]. 
Thus, the drug has been listed in the future perspec-
tives of 2019 ESC/EAS Guidelines for new approaches 
to reduce low-density lipoprotein cholesterol [18]. In 
2020, the Food and Drug Administration (FDA) has 
approved bempedoic acid for the treatment of adults who 
require additional low-density lipoprotein-cholesterol 
lowering [19], and European Medicines Agency (EMA) 
has recommended approval bempedoic acid to treat 
adults with primary hypercholesterolemia and mixed 
dyslipidemia [20]. However, the benefites of bempedoic 
acid are limited, because current trials have not proved 
the potential benefits of bempedoic acid use for preven-
tion of cardiovascular events [7, 13]. The primary criti-
cisms of those trials have been small numbers of events, 
raising the probability of a type II error. We performed 
the systematic review and meta-analysis to evaluate the 
potential benefit and safety of bempedoic acid use for the 
prevention of cardiovascular events.
Methods
Protocol and guidance
The protocol of this study was registered in Open Science 
Framework (https ://osf.io/va34s ). The methods of report-
ing systematic review followed PRISMA guidelines [21].
Eligibility criteria
Inclusion Criteria: Eligible studies met the following 
PICOS (Patients, Intervention, Comparison Outcomes, 
and Study design) criteria: (1) Population: statin-intoler-
ant patients or patients that are on statins, with hyper-
cholesterolemia (age ≥ 18); (2) Intervention: bempedoic 
acid; (3) Comparison intervention: placebo or no treat-
ment; (4) Outcomes: at least one outcome of interest had 
to be reported. (5) Study design: randomized controlled 
trials.
Outcomes
The primary outcomes were major adverse cardiac event 
(defined as a composite of cardiovascular death, myocar-
dial infarction, nonfatal stroke, hospitalization for unsta-
ble angina, and coronary revascularization. Follow-up of 
the cardiovascular events should be at least 12  months 
or 48  weeks), and percent change from baseline to the 
respective study endpoints in low-density lipoprotein 
cholesterol (LDL-C). Secondary event outcomes were 
cardiovascular death, myocardial infarction, nonfatal 
stroke, hospitalization for unstable angina, coronary 
revascularization, percent change in C-reactive protein 
(CRP), and new-onset or worsening diabetes. Second-
ary safety outcomes were any adverse event, serious 
adverse event, muscular-related adverse event, decrease 
in glomerular filtration rate, increase in blood creati-
nine, increase in blood uric acid, gout, neurocognitive 
disorders, ALT or AST > 3 × ULN, and creatine kinase 
(CK) > 5 × ULN. These outcomes may be defined in indi-
vidual trials with variations.
Information sources and search strategy
We searched the electronic databases Medline, Embase, 
Cochrane Library of Clinical Trials from inception until 
March 3, 2020. Relevant clinical trial registries (Clinical-
Trials.gov) were consulted regarding any ongoing stud-
ies or the availability of completed studies with reported 
results. We also checked the reference lists of eligible 
studies and screened scientific abstracts. We did not 
use any language or publication status restrictions. The 
details of the search strategy conducted are presented in 
Additional file 1. Table S1.
Study selection
Two authors (YZ and XW) evaluated eligibility inde-
pendently based on titles and abstracts of all reports 
retrieved in the electronic search. They screened the 
full text for potentially relevant trials when both agreed 
that a citation met the eligibility criteria. Discrepancies 
were resolved by consensus among the study team. The 
corresponding authors were contacted to obtain miss-
ing information and unpublished data when needed, to 
assess the inclusion criteria or when suitable data were 
not available.
Data collection process
Data were extracted using piloted forms, independently 
and in duplicate by the two authors (YZ and XW). Dis-
crepancies were resolved by consensus among the study 
team.
Assessment of risk of bias and quality of evidence
Two authors (YZ and XW) examined eligible studies 
independently using the Cochrane risk of bias assess-
ment tool [22]. We assessed the following domains for 
each study: (1) random sequence generation, (2) alloca-
tion sequence concealment, (3) blinding of participants 
and personnel, (4) blinding of outcome assessment, (5) 
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completeness of outcome data, (6) selective reporting, 
and (7) other sources of bias. Each domain was assessed 
as either low, unclear, or high risk of bias. The highest 
risk of bias for any criteria was used to reflect the overall 
risk of bias for the study.
Two authors (YZ and XW) used the Grading of Recom-
mendations, Assessment, Development and Evaluation 
(GRADE) approach to rate the quality of evidence and 
generate absolute estimates of effect for the outcomes, 
taking into account study limitations (risk of bias), incon-
sistency, imprecision, indirectness, and publication bias 
[23].
Statistical analysis
The statistical analyses were performed using RevMan 
(5.3.3; The Cochrane Collaboration) and the meta pack-
age in R (version 3.4.3; R Project for Statistical Comput-
ing). Random-effects models were used for all outcomes. 
Dichotomous variables were analyzed using the Man-
tel–Haenszel method and were expressed as risk ratios 
(RR). Continuous variables were expressed as mean dif-
ferences. Statistical significance testing was 2-sided and 
P < 0.05 was considered statistically significant. Heteroge-
neity was assessed using with the χ2 test and the  I2  test, 
with I2 > 50% being considered substantial [24]. The pos-
sibility of publication bias was evaluated by a visual esti-
mate of the funnel plot and by the regression tests Egger 
test, Begg test, and Harbord test when ten or more trials 
were pooled [25]. Analyses for all outcomes were done on 
an intention-to-treat basis.
Sensitivity analyses
Sensitivity analyses were conducted for the primary out-
come by (1) excluding trials with unclear or higher risk 
of bias (2) using inverse variance method; and (3) using 
fixed-effect models.
Subgroup analysis
We planned subgroup analyses for major adverse car-
diac event and percent change in LDL-C for the follow-
ing variables: (1) whether patients with a history of statin 
intolerance; (2) whether treatment with a combination 
of bempedoic acid and ezetimibe; (3) whether treatment 
with a combination of bempedoic acid and maximally 
tolerated statin therapy; (4) whether treatment with 
stains as background therapy.
Results
Description of included studies
We identified 106 records. After screening, eleven trials 
[5–15] with a total of 4391 participants met our inclu-
sion criteria. Figure 1 details the study selection process. 
Descriptive details of the eligible trials are presented in 
Table 1. Study sizes ranged from 56 to 2230 participants; 
the mean age ranged from 53.3 to 64.7 years; the percent-
age of female ranged from 26.1 to 63.6%. Two trials [7, 
13] have a follow-up period of at least 1  year, whereas 
nine trial [5, 6, 8–12, 14, 15] have follow-up periods less 
than 1 year.
Risk of bias and quality of evidence
The overall quality of the 11 included trials was mod-
erate (Figure S1 and S2 in the Additional file  1.); 6 tri-
als [6, 7, 10, 13–15] had low risk of bias, 1 trial [8] had 
unclear risk of bias, and 4 trials [5, 9, 11, 12] had high risk 
of bias. Table 2 shows a summary of findings for all out-
comes. The quality of evidence assessed with the GRADE 
approach was high for major adverse cardiac events.
Cardiovascular events
There were 2 trials [7, 13], including a total of 3008 par-
ticipants with data available regarding major adverse 
cardiovascular events. Specifically, we performed a com-
posite tally of cardiovascular death, myocardial infarc-
tion, nonfatal stroke, hospitalization for unstable angina, 
and coronary revascularization. The use of bempedoic 
acid was associated with reductions in the composite car-
diovascular outcome (RR 0.75, 95% CI 0.56–0.99;  I2 = 0%; 
Fig.  2). Other cardiovascular events were reported in 
Table  2. The use of bempedoic acid was not associated 
with reductions in cardiovascular death, myocardial 
infarction, nonfatal stroke, hospitalization for unsta-
ble angina, and coronary revascularization, compared 
individually with placebo (Additional file  1. Figure S3–
S7). Subgroup analysis for major adverse cardiovascular 
events did not detect any beneficial effect in any specific 
subgroups (Additional file 1. Figure S8).
Percent change in LDL‑C and CRP
There were 9 trials [6, 8, 12, 26–31], including a total of 
3957 participants with data available regarding the per-
cent change in LDL-C from baseline to the respective 
study endpoints. The pooled results showed that using 
bempedoic acid resulted in lower LDL-C compared 
with placebo, with a mean difference of 22.91% (95% CI 
−  27.35 to −  18.47%;  I2 = 99%; Fig.  3). Subgroup analy-
sis for percent change in LDL-C revealed subgroup of 
no stains using as background therapy benefit more on 
LDL-C lowering (P = 0.03; Additional file Figure S9). 
Seven trials including 3555 participants reported percent 
change in CRP. The pooled results showed that bempe-
doic acid reduced CRP levels compared with placebo, 
with a mean difference of 24.70% (95% CI −  32.10 to 
− 17.30%;  I2 = 53%; Additional file 1. Figure S10).
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New‑onset or worsening diabetes
For the outcome of new-onset or worsening diabetes, 
four studies [7, 10, 11, 13] reported a total of 161 events 
[92/2424 (3.7%) with bempedoic acid and 69/1197 
(5.7%) with placebo]. The use of bempedoic acid was 
associated with a reduction in new-onset or worsening 
diabetes (RR 0.65, 95% CI 0.44–0.96;  I2 = 23%; Fig. 4).
Safety outcomes
Table 2 summarized findings of safety outcomes. Bem-
pedoic acid was associated with elevated levels of blood 
uric acid (Additional file  1. Figure S11), but not asso-
ciated with a decrease in glomerular filtration rate. 
Bempedoic acid was not associated with an increased 
incidence of any adverse event, serious adverse event 
or muscle-related adverse event. Also, bempedoic 
acid was not associated with increased blood creati-
nine, gout, neurocognitive disorders, incidence of 
ALT or AST > 3 × ULN, or incidence of creatine kinase 
(CK) > 5 × ULN (Additional file 1. Figure S12–S20).
Sensitivity analysis
Similar results were observed for the composite cardio-
vascular outcome in all conducted sensitivity analyses 
by excluding trials with unclear or higher risk of bias, 
using inverse variance method, and using fixed-effect 
models (Additional file 1. Table S2).
Fig. 1 Flow diagram showing final included and excluded studies
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Discussion
In this meta-analysis of 11 RCTs enrolling 4391 patients, 
the use of bempedoic acid was associated with reduc-
tions in the composite cardiovascular outcome consisting 
of cardiovascular death, myocardial infarction, nonfatal 
stroke, hospitalization for unstable angina, and coronary 
revascularization in statin-intolerant patients with hyper-
cholesterolemia. Moreover, bempedoic acid use was 
associated with a reduced risk of diabetes.
Comparison with existing data
To the best of our knowledge, this study is the first 
meta-analysis assessing the effect of bempedoic acid 
on cardiovascular events. The previous meta-analysis 
has evaluated the use of bempedoic acid to reduce LDL 
cholesterol [17], and had analyzed 5 trials with a total of 
625 patients with hypercholesterolemia, concluding that 
bempedoic acid led to significantly lower LDL cholesterol 
levels without adverse events. The previous review did 
not assess the efficacy of bempedoic acid on cardiovas-
cular events and may be underpowered to assess adverse 
drug events due to the small sample size [17].
This study builds on the previous meta-analysis mainly 
through the inclusion of two large trials [7, 13], the 
CLEAR Harmony trial [13] and the CLEAR Wisdom trial 
[7]. However, both trials were not designed to assess the 
effect on cardiovascular events, and thus, individually did 
not observe significant between-group differences in the 
incidence of cardiovascular events.
Another important finding of our analysis is that bem-
pedoic acid was associated with a reduction in new-onset 
or worsening diabetes. This phenomenon may be related 
to AMP-activated protein kinase (AMPK), since bempe-
doic acid plays a dual role in both activation of hepatic 
AMPK signaling pathway and inhibitory activity against 
hepatic ATP-citrate lyase (ACL) [32, 33].
Strengths and limitations
The major strength in our review is the strict methodol-
ogy implemented which followed the recommendations 
of the Cochrane Collaboration and PRISMA statement, 
including a protocol, an up-to-date literature search and 
study selection, data extraction and risk of bias assess-
ment by two independent investigators. We also included 
Table 1 Characteristics of studies included in the systematic review
NR not reported, BMI body-mass index, LDL- low-density lipoprotein cholesterol
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GRADE to assess the degree of certainty in pooled esti-
mates of effect and presented absolute and relative risks.
This study has several limitations. First, the cardiovas-
cular outcomes might be imprecise, seen as a wider CI 
around the estimate of the effect, due to the relatively 
few patients included. We have downgraded the quality 
of evidence of these outcomes due to imprecision of the 
individual studies.
Second, there is significant clinical heterogeneity in 
the bempedoic acid dose utilized, duration of treatment, 
and outcome definitions across the trials included in this 
meta-analysis.
Third, only 2 trials reported data with 1  year of fol-
low-up, but other trials had less. More trials with longer 
follow-up are required to examine whether the benefits 
of bempedoic acid are enhanced over time and whether 
bempedoic acid can ultimately lower the rate of mortality.
Fourth, the small number of trials included to analyze 
the major adverse cardiac events led to the inability to 
detect the presence of publication bias. However, the risk 
Table 2 Summary of findings and strength of evidence in studies
LDL-C Low density lipoprotein cholesterol, CRP C-reactive protein, CK Creatine kinase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ULN Upper limit 








RR/MD (95% CI) I2 Absolute effect estimates (per 1000) Quality 
of the evidence
Intervention Control Difference
Cardiovascular events 3008 (2) 0.75 [0.56, 0.99] 0% 56 74 − 19 [− 1, − 33] High
Percent change of LDL-C 3957 (9) − 22.91 [− 27.35, − 18.47] 99% – – – Moderate#
New-onset or worsening diabetes 3621 (4) 0.65 [0.44, 0.96] 23% 38 58 − 20 [− 2, − 32] Moderate§
Percent change of CRP 3555 (7) − 24.70 [− 32.10, − 17.30] 53% – – – Moderate#
Myocardial infarction 3008 (2) 0.54 [0.25, 1.15] 37% 12 22 − 10 [− 17, 3] Moderate§,#
Coronary revascularization 3008 (2) 0.74 [0.50, 1.10] 0% 29 39 − 10 [− 20, 4] Moderate§
Cardiovascular death 3008 (2) 1.65 [0.46, 5.98] 0% 5 3 2 [− 2, 15] Moderate§
Nonfatal stroke 3008 (2) 1.11 [0.34, 3.61] 0% 4 4 0 [− 3, 10] Moderate§
Hospitalization for unstable angina 2574 (2) 0.84 [0.41, 1.73] 51% 11 13 − 2[− 8, 9] Low#,§
Any adverse event 4188 (9) 1.01 [0.97, 1.05] 40% 712 705 7 [− 21, 35] Low&,#
Serious adverse event 4184 (9) 1.06 [0.89, 1.26] 0% 126 119 7 [− 13, 31] Moderate&
Muscular-related adverse event 2703 (3) 1.12 [0.80, 1.56] 26% 120 107 13 [− 21, 60] Moderate§
Decrease in glomerular filtration rate 3276 (3) 3.61 [0.81, 16.04] 0% 4 1 3 [− 1, 14] Low*
Increase in blood creatinine 3482 (4) 2.15[0.81, 5.69] 0% 6 3 3 [− 1, 16] Moderate§
Increase in blood uric acid 1176 (3) 3.76 [1.24, 11.39] 0% 30 8 22 [2,81] Low*
Gout 3421 (4) 2.37 [0.88, 6.36] 12% 12 5 7 [− 1, 43] Moderate§
Neurocognitive disorders 3076 (3) 0.94 [0.41, 2.17] 0% 8 8 0 [− 5, 9] Moderate§
ALT or AST > 3 × ULN 3382 (5) 1.97 [0.61, 6.34] 0% 6 3 3 [− 1, 14] Moderate§
CK > 5 × ULN 3382 (5) 1.31 [0.23, 7.50] 19% 3 2 1 [− 1, 12] Moderate§
Fig. 2 Random-effects meta-analysis of bempedoic acid on composite cardiovascular outcome
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of publication bias was low because all trials individually 
had negative results in the major adverse cardiac events.
Fifth, heterogeneity might exist in the outcome of 
new-onset or worsening diabetes. The two largest tri-
als varied in the effect point of new-onset or worsening 
diabetes (RR 0.93 vs RR 0.61), with some statistical het-
erogeneity  (I2 = 23%). We have downgraded the quality of 
evidence of new-onset or worsening diabetes because of 
inconsistencies.
Future research and other pharmacotherapies
The results of the present meta-analysis indicate that 
more clinical trials are warranted to investigate remain-
ing questions about the potentially beneficial effect of 
bempedoic acid on cardiovascular outcomes. Major 
variations in the study protocols of these trials included 
in the meta-analysis indicate that the optimal dosing of 
bempedoic acid remains uncertain. Likewise, it is uncer-
tain if there are subgroups of patients who are more likely 
to benefit from bempedoic acid. Moreover, longer follow-
ups could help provide much-needed data on the effec-
tiveness on cardiovascular outcomes, long-term safety, 
and tolerability of bempedoic acid.
In addition to bempedoic acid [34, 35], there are many 
novel therapeutic drugs that have demonstrated the 
ability to lower LDL-C levels or further reduce the risk 
of major cardiovascular events in both non-diabetic 
patients and diabetic patients [36–38]. These drugs span 
a variety of mechanisms, such as proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitor [39, 40], per-
oxisome proliferators-activated receptor (PPAR) inhibi-
tor [41, 42], and IL-1β inhibitor [43]. Many of the novel 
therapeutic agents are undergoing clinical evaluation, 
and some of them have already approved by the FDA. 
The use of non-statin therapies for primary prevention 
of hyperlipidemia in subpopulations of patients who do 
not tolerate statins remain an area of active investigation, 
and clinicians should still refer to existing guidelines for 
initial pharmacotherapeutic selection in patients with 
hyperlipidemia.
Conclusions
The use of bempedoic acid in patients with hypercho-
lesterolemia was associated with a lower risk of cardio-
vascular events and DM. Morevover, bempedoic acid 
resulted in a significant lowering of LDL-C level and CRP 
level. More trials with longer follow-ups are needed to 
confirm the overall result and identify subgroups that 
benefit the most from the use of bempedoic acid.
Fig. 3 Random-effects meta-analysis of bempedoic acid on percent change in LDL-C. LDL-C Low density lipoprotein cholesterol
Fig. 4 Random-effects meta-analysis of bempedoic acid on new-onset or worsening diabetes
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